Background: Malignant pleural effusion typically is a sign of aggressive and advance disease with generally short life expectancy. This cause a lot of burden symptomatically to patients with advance malignancy. Hence, a lot of patients are made known early to palliative service to help optimizing patients’ symptomology. One of the procedures to help preventing recurrence of symptomatic malignant pleural effusion is bedside chemical pleurodesis following thoracocentesis. The aim of this audit is to assess our efficacy and safety of doing the above procedure in a palliative setting.

Patients and methods: Retrospective electronic records of patients were reviewed from January 2020 until March 2022. Malignant pleural effusion were confirm by cytological assessment of pleural fluid following chest tube drainage. Chemical pleurodesis was done by pleural fluid instillation of bleomycin, performed bedside by palliative physicians.

Results: Twenty patients were identified with 7 cases were male and 13 cases were female. Mean age was 69.2 with 55% of them suffered from lung malignancy. Complete response is seen in 45% and partial response is seen in 20%. Failure rate is at 35%. The complications were minimal with only 5% of patient had fever and 10% had pleuritic pain.

Conclusions: The audit shows bedside chemical pleurodesis perform by palliative physicians is as efficacious and safe comparing to when it is done by other specialties. It helps improve symptoms to 65% of our patient and thus improve quality of life.